Beyondspring Inc
Veridion Score
BETALOW CONF · 4/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is BYSI moving today?
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
BYSI overview
Related filings and maps
Congress activity in BYSI
No receipt-qualified Congressional disclosure is present for BYSI in the cached public ledger.
BYSI contract awards, year to date.
Public federal awards linked to this ticker.
BYSI lobbying filings, year to date.
Registered lobbying filings matched to Beyondspring Inc.